ressants, before they can be approved for marketing in the U.S.In a meeting scheduled for Oct. 25, the FDA will ask an advisory committee about its move toward longer-term studies of antidepressants, antipsychotics and other drugs for long-term psychiatric conditions, including how such trials should be designed.